APA (7th ed.) Citation

V, D. F., A, C., G, A., M, S., M, G., M, O., . . . T, T. (2026). Adjuvant immunotherapy in high-risk stage II melanoma: Real-world outcomes from a large multicenter retrospective study. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-026-04466-0

Chicago Style (17th ed.) Citation

V, De Falco, et al. "Adjuvant Immunotherapy in High-risk Stage II Melanoma: Real-world Outcomes from a Large Multicenter Retrospective Study." Cancer Immunology, Immunotherapy : CII 2026. https://doi.org/10.1007/s00262-026-04466-0.

MLA (9th ed.) Citation

V, De Falco, et al. "Adjuvant Immunotherapy in High-risk Stage II Melanoma: Real-world Outcomes from a Large Multicenter Retrospective Study." Cancer Immunology, Immunotherapy : CII, 2026, https://doi.org/10.1007/s00262-026-04466-0.